迈向子宫平滑肌瘤的个体化医疗
子宫平滑肌瘤症状多样、子宫与肌瘤特征各异且治疗选择众多,但全子宫切除术仍占所有手术治疗近四分之三;随着对全子宫切除术长期风险及肌瘤生物学的新认识,个体化医疗方法可能在不远的将来出现。驱动突变、平滑肌细胞与成纤维细胞相互作用及类固醇激素反应性等生物学特征可能助力个体化治疗,而先进影像学有望预测肌瘤亚型及治疗反应。
要点
- 全子宫切除术仍占子宫平滑肌瘤所有手术治疗近四分之三。
- 驱动突变及平滑肌细胞与成纤维细胞相互作用等生物学特征可能助力个体化治疗。
- 先进影像学有望预测肌瘤亚型、治疗反应或两者。
核心结论
- 随着对全子宫切除术长期风险及平滑肌肌瘤生物学的新认识,个体化医疗方法可能在不远的将来出现。
- 我们预测治疗将从切除或介入治疗继续向药物治疗演变,并最终实现高危个体的预测。
- 理想情况下,个体化治疗将为平滑肌瘤高危女性提供一级预防,并在初始治疗后提供二级预防。
研究设计与样本
- 本文为关于子宫平滑肌瘤个体化医疗的综述。
- 原文未报告检索范围。
主要发现
- 尽管症状广泛、子宫与肌瘤特征各异且替代方案众多,全子宫切除术仍占所有手术治疗近四分之三。
- 有越来越多的证据支持多种针对症状性平滑肌瘤的操作性治疗,以及新一代药物治疗正在开发中。
- 影响该疾病过程的关键生物学特征包括常见驱动突变,以及对平滑肌细胞与成纤维细胞相互作用的新认识。
- 细胞类型间的相互作用与类固醇激素反应性可能在发病机制中起作用,并可用于个体化治疗。
- 鉴于同一子宫内平滑肌瘤具有独立的克隆性质,对个体平滑肌瘤进行活检以了解其生物学不太可能取得成果。
临床怎么用
- 原文未据此给出推荐。
局限性
- 鉴于同一子宫内平滑肌瘤具有独立的克隆性质,对个体平滑肌瘤进行活检以了解其生物学不太可能取得成果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Uterine leiomyomas are common and life-altering for many women. Despite a wide range of symptoms, varying characteristics of the uterus and the leiomyomas themselves, and many alternatives, hysterectomy accounts for almost three fourths of all surgical therapy, yet there is increasing evidence for a variety of procedural therapies for symptomatic leiomyomas and a new generation of medical therapies under development. With increasing evidence of long-term risk from hysterectomy and new data regarding leiomyoma biology, individualized medical approaches to leiomyomas are likely in the near future. Key biological attributes that influence this disease process are common driver mutations and the new appreciation of the interaction of smooth muscle cells and fibroblasts. Additionally, the interaction between cell types and steroid hormone responsiveness likely plays a role in pathogenesis that can be leveraged in individualized therapy. However, given the independent clonal nature of leiomyomas within the same uterus, moving in the direction of biopsies for individual leiomyomas to understand the biology is unlikely to be fruitful. Use of advanced imaging will likely continue to evolve not only to accurately predict malignant disease, including sarcomas, but to predict leiomyoma subtypes, response to therapy, or both. We predict the continued evolution of therapy from excisional or interventional therapies to medical therapies and ultimately prediction of at-risk individuals. Ideally, individualized therapies will offer primary prevention for women at high risk of leiomyomas and secondary prevention after initial treatment.
引用
- Laughlin-Tommaso SK, Stewart EA. Moving Toward Individualized Medicine for Uterine Leiomyomas. Obstet Gynecol. 2018. PMID: 30130343. doi:10.1097/AOG.0000000000002785
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。